Detailed information for compound 1835881
Basic information
Technical information
- Name: Unnamed compound
- MW: 322.444 | Formula: C21H26N2O
-
H donors: 1
H acceptors: 0
LogP: 3.8
Rotable bonds: 4
Rule of 5 violations (Lipinski): 1 - SMILES: CN1[C@@H]2CC[C@H]1C[C@H](C2)OC(c1ccccc1N)c1ccccc1
- InChi: 1S/C21H26N2O/c1-23-16-11-12-17(23)14-18(13-16)24-21(15-7-3-2-4-8-15)19-9-5-6-10-20(19)22/h2-10,16-18,21H,11-14,22H2,1H3/t16-,17+,18+,21?
- InChiKey: KZFDKINRISJFCO-TWYXQDJOSA-N
Network
Hover on a compound node to display the structore
Synonyms
No synonyms found for this compound
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Rattus norvegicus | Muscarinic acetylcholine receptor M1 | Starlite/ChEMBL | References |
| Homo sapiens | transient receptor potential cation channel, subfamily V, member 1 | Starlite/ChEMBL | No references |
| Homo sapiens | mechanistic target of rapamycin (serine/threonine kinase) | Starlite/ChEMBL | No references |
| Homo sapiens | potassium voltage-gated channel, subfamily H (eag-related), member 2 | Starlite/ChEMBL | No references |
| Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
| Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
| Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
| Rattus norvegicus | Dopamine transporter | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0175789 | 0.275093 | 1 |
| Giardia lamblia | Cathepsin B precursor | 0.00763636 | 0.0969932 | 0.5 |
| Toxoplasma gondii | cathepsin B | 0.00763636 | 0.0969932 | 0.5 |
| Echinococcus granulosus | integrin beta 2 | 0.0133808 | 0.199892 | 0.70961 |
| Loa Loa (eye worm) | hypothetical protein | 0.00305538 | 0.0149346 | 0.0528774 |
| Echinococcus multilocularis | cathepsin b | 0.0175789 | 0.275093 | 1 |
| Giardia lamblia | Cathepsin B precursor | 0.00763636 | 0.0969932 | 0.5 |
| Trypanosoma brucei | cysteine peptidase C (CPC) | 0.00763636 | 0.0969932 | 0.5 |
| Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0175789 | 0.275093 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.00270135 | 0.00859296 | 0.0304242 |
| Mycobacterium tuberculosis | Probable oxidoreductase | 0.0580474 | 1 | 0.5 |
| Giardia lamblia | Cathepsin B precursor | 0.00763636 | 0.0969932 | 0.5 |
| Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.00763636 | 0.0969932 | 0.315418 |
| Brugia malayi | calpain family protein 1 | 0.00305538 | 0.0149346 | 0.0231577 |
| Echinococcus multilocularis | calpain A | 0.00312204 | 0.0161287 | 0.0586299 |
| Echinococcus multilocularis | integrin beta 2 | 0.0133808 | 0.199892 | 0.726636 |
| Schistosoma mansoni | integrin beta subunit | 0.0106794 | 0.151503 | 0.524945 |
| Trichomonas vaginalis | Clan CA, family C1, cathepsin B-like cysteine peptidase | 0.00763636 | 0.0969932 | 0.5 |
| Loa Loa (eye worm) | hypothetical protein | 0.00250425 | 0.00506225 | 0.0179234 |
| Trypanosoma cruzi | cysteine peptidase C (CPC), putative | 0.0175789 | 0.275093 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0175789 | 0.275093 | 0.973993 |
| Mycobacterium ulcerans | short chain dehydrogenase | 0.0580474 | 1 | 0.5 |
| Schistosoma mansoni | family C2 unassigned peptidase (C02 family) | 0.00312204 | 0.0161287 | 0.00458976 |
| Brugia malayi | Integrin beta pat-3 precursor | 0.017989 | 0.282438 | 1 |
| Echinococcus multilocularis | cathepsin b | 0.0175789 | 0.275093 | 1 |
| Loa Loa (eye worm) | cathepsin B | 0.00763636 | 0.0969932 | 0.343414 |
| Loa Loa (eye worm) | integrin beta-2 | 0.017989 | 0.282438 | 1 |
| Leishmania major | cysteine peptidase C (CPC),CPC cysteine peptidase, Clan CA, family C1, Cathepsin B-like | 0.00763636 | 0.0969932 | 0.5 |
| Brugia malayi | calpain family protein 1 | 0.00305538 | 0.0149346 | 0.0231577 |
| Schistosoma mansoni | family C2 unassigned peptidase (C02 family) | 0.00312204 | 0.0161287 | 0.00458976 |
| Loa Loa (eye worm) | calpain family protein 1 | 0.00305538 | 0.0149346 | 0.0528774 |
| Echinococcus multilocularis | family C2 unassigned peptidase (C02 family) | 0.00312204 | 0.0161287 | 0.0586299 |
| Loa Loa (eye worm) | kelch domain-containing protein family protein | 0.00270135 | 0.00859296 | 0.0304242 |
| Echinococcus granulosus | cathepsin b | 0.0175789 | 0.275093 | 1 |
| Echinococcus granulosus | cathepsin b | 0.0175789 | 0.275093 | 1 |
| Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0175789 | 0.275093 | 1 |
| Brugia malayi | cathepsin B-like cysteine proteinase | 0.0175789 | 0.275093 | 0.973176 |
| Schistosoma mansoni | SmCB2 peptidase (C01 family) | 0.0175789 | 0.275093 | 1 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Activity (functional) | Cytoprotection against glutamate-induced toxicity in laboratory prepared food feeded Fmr1 null mutant Drosophila Fmr1'3/TM6C fragile X syndrome model assessed as embryo viability at 40 uM in presence of 40 uM GABAB receptor antagonist CGP-54626 by flow cytometry relative to untreated embryos | ChEMBL. | 18327252 | |
| Activity (functional) | Suppression of Futsch protein overexpression in head lysates of laboratory prepared food feeded Fmr1 null mutant Drosophila Fmr1'3/TM6C fragile X syndrome model at 40 uM by Western blot | ChEMBL. | 18327252 | |
| Activity (functional) | = 25 % | Protection against fragile X syndrome phenotypes in Fmr1 null mutant Drosophila Fmr1'3/TM6C assessed as embryo viability at 40 uM at 25 degC by flow cytometry relative to untreated homozygous embryos | ChEMBL. | 18327252 |
| Activity (functional) | = 66.38 % | Protection against fragile X syndrome phenotypes in laboratory prepared food feeded Fmr1 null mutant Drosophila Fmr1'3/TM6C assessed as homozygous Fmr1-/- embryo viability at 40 uM at 25 degC by flow cytometry relative to untreated homozygous embryos fed with only laboratory prepared food | ChEMBL. | 18327252 |
| I (binding) | = 14 % | Percent inhibition at 10 microM for displacement of [3H]- desmethylimipramine binding at the norepinephrine transporter(NET) in rat cortex. | ChEMBL. | 9083473 |
| I (binding) | = 16 % | Percent inhibition at 10 microM for displacement of [3H]- citalopram binding at the serotonin transporter (5HTT). | ChEMBL. | 9083473 |
| IC50 (functional) | = -5.6 | Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay | ChEMBL. | 19734910 |
| IC50 (functional) | = -5.1 | Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay | ChEMBL. | 19734910 |
| IC50 (functional) | = -5.1 | Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay | ChEMBL. | 19734910 |
| IC50 (functional) | = -5 | Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay | ChEMBL. | 19734910 |
| IC50 (functional) | = -5 | Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay | ChEMBL. | 19734910 |
| IC50 (functional) | = 373 nM | Inhibition of [3H]-dopamine uptake in rat caudate putamen tissue. | ChEMBL. | 10479283 |
| IC50 (functional) | = 373 nM | [3H]-Dopamine uptake inhibition in rat caudate putamen | ChEMBL. | 9083473 |
| Inhibition (ADMET) | = 75.3252408 % | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | ChEMBL. | 23571415 |
| Inhibition (ADMET) | = 77.23313815 % | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | ChEMBL. | 23571415 |
| Ki (binding) | = -5.73 | Binding affinity to dopamine transporter (DAT) using [3H]-WIN- 35428 as a radioligand | ChEMBL. | 11063611 |
| Ki (binding) | = 1.12 nM | Displacement of [3H]-pirenzepine binding at muscarinic Muscarinic acetylcholine receptor M1 in rat brain P2 membranes. | ChEMBL. | 9083473 |
| Ki (binding) | = 1840 nM | Displacement of [3H]-WIN- 35,428 binding to the dopamine transporter in rat caudate putamen tissue. | ChEMBL. | 10479283 |
| Ki (binding) | = 1840 nM | Displacement of [3H]-WIN- 35,428 binding to the dopamine transporter (DAT) in Rat Caudate Putamen | ChEMBL. | 9083473 |
| Potency (functional) | 4.6109 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
| Potency (functional) | = 6.3096 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
| Potency (functional) | 6.5131 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
| Potency (functional) | 11.2202 uM | PUBCHEM_BIOASSAY: qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
| Potency (functional) | 11.5774 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
| Potency (functional) | 12.5893 uM | PUBCHEM_BIOASSAY: HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488988] | ChEMBL. | No reference |
| Potency (functional) | 14.1254 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
| Potency (functional) | = 18.4927 um | PUBCHEM_BIOASSAY: Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
| Potency (functional) | 22.3872 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of ATXN expression: Validation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588349, AID588380] | ChEMBL. | No reference |
| Potency (functional) | 25.1189 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588378, AID588380] | ChEMBL. | No reference |
| Potency (functional) | = 44.6684 um | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization. (Class of assay: confirmatory) [Related pubchem assays: 596 ] | ChEMBL. | No reference |
| Potency (functional) | = 84.9214 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
| Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
| Selectivity ratio (functional) | = 0.2 | Selectivity ratio for [3H]-DA uptake inhibition to DAT binding | ChEMBL. | 9083473 |
Phenotypes
Whole-cell/tissue/organism interactions
| Species name | Source | Reference | Is orphan |
|---|---|---|---|
| Homo sapiens | ChEMBL23 | ||
| Plasmodium falciparum | ChEMBL23 | 19734910 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL3084891
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.